Point72 Europe London LLP Has $852,000 Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

Point72 Europe London LLP decreased its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 29.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,420 shares of the company's stock after selling 13,413 shares during the period. Point72 Europe London LLP owned 0.05% of Structure Therapeutics worth $852,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Spire Wealth Management bought a new stake in Structure Therapeutics in the fourth quarter valued at about $243,000. JPMorgan Chase & Co. grew its position in shares of Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock worth $1,489,000 after buying an additional 25,500 shares during the period. Mariner LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $665,000. Barclays PLC increased its stake in shares of Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company's stock valued at $3,562,000 after acquiring an additional 31,815 shares during the last quarter. Finally, Invesco Ltd. raised its position in shares of Structure Therapeutics by 4.1% in the 4th quarter. Invesco Ltd. now owns 371,767 shares of the company's stock valued at $10,082,000 after acquiring an additional 14,559 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Stock Down 2.7%

GPCR traded down $0.67 during trading on Wednesday, hitting $24.01. The company had a trading volume of 284,381 shares, compared to its average volume of 930,952. The company has a market capitalization of $1.38 billion, a PE ratio of -32.49 and a beta of -1.69. Structure Therapeutics Inc. has a one year low of $13.22 and a one year high of $62.74. The firm's 50-day moving average price is $21.34 and its 200 day moving average price is $26.24.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Sell-side analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on GPCR. Citigroup began coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective for the company. William Blair initiated coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, HC Wainwright dropped their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of "Buy" and a consensus target price of $78.00.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.